Radioimmunotherapy of Nude Mice Bearing a Human Interieukin 2 Receptor α-expressing Lymphoma Utilizing the α-emitting Radionuclide-conjugated Monoclonal Antibody 212Bi-anti-Tac

Cancer Research

Volumn 54, Issue 16, 1994, Pages 4362-4370

  Hartmann, Frank ^a   Horak, Eva M ^a   Garmestani, Kayhan ^a   Wu, Chuanchu ^a   Brechbiel, Martin W ^a   Kozak, Robert W ^b   Tso, J ^c   Kosteiny, Sheri A ^c   Gansow, Otto A ^a   Nelson, David L ^a   Waldmann, Thomas A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^c PROTEIN DESIGN LABS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISMUTH 212; CESIUM 137; INTERLEUKIN 2 RECEPTOR; IODINE 125; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; GAMMA IRRADIATION; INTRAVENOUS DRUG ADMINISTRATION; ISOTOPE LABELING; LYMPHOMA; LYMPHOMA CELL LINE; MOUSE; NONHUMAN; NUDE MOUSE; PLASMACYTOMA; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; RADIOSENSITIVITY; SOLID TUMOR;

ANIMAL; ANTIBODIES, MONOCLONAL; BISMUTH; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DRUG SCREENING ASSAYS, ANTITUMOR; HUMAN; LEUKEMIA-LYMPHOMA, T-CELL, ACUTE, HTLV-I-ASSOCIATED; MICE; MICE, NUDE; RADIOIMMUNOTHERAPY; RADIOISOTOPES; RADIOTHERAPY DOSAGE; RECEPTORS, INTERLEUKIN-2; TISSUE DISTRIBUTION;

EID: 0028070359     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Köhler, G., and Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature (Lond.), 256: 495-497, 1975.
2. Cantane, R., and Longo, D. L. Monoclonal antibodies for cancer therapy. Isr. J. Med. Sci., 24: 471-476, 1988.
3. Waldmann, T. A. Monoclonal antibodies in diagnosis and therapy. Science (Washington DC), 252: 1659-1662, 1991.
4. Jones, P. T., Dear, P. H., Foote, J., Neuberger, M. S., and Winter, G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature (Lond.), 321: 522-525, 1986.
5. Queen, C., Schneider, W. P., Selick, H. E., Payne, P. W., Landolfi, N. F., Duncan, J. F., Avdalovic, N. M., Levitt, M., Junghans, R. P., and Waldmann, T. A. A humanized antibody that binds to the IL-2 receptor. Proc. Natl. Acad. Sci. USA, 86: 10029-10033, 1989.
6. Chaudhary, V. K., Queen, C., Junghans, R. P., Waldmann, T. A., FitzGerald, D. J., and Pastan, I. A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. Nature (Lond.), 339: 394-397, 1989.
7. Vitetta, E. S., Fulton, R., May, R. D., Till, M., and Uhr, J. W. Redesigning nature's posions to create anti-tumor reagents. Science (Washington DC), 238: 1098-1104, 1987.
8. Wilbur, S. Potential use of a emitting radionuclides in the treatment of cancer. Antibody Immunoconj. Radiopharmaceuticals., 4: 85-92, 1991.
9. Press, O. W., Eary, J. F., Badger, C. C., Martin, P. J., Appelbaum, F. R., Levy, R., Miller, R., Brown, S., Nelp, W. B., Krohn, K. A., Fisher, D., DeSantes, K., Porter, B., Kidd, P., Thomas, E. D., and Bernstein, I. D. Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti CD-37) antibody. J. Clin. Oncol., 7: 1027-1038, 1989.
10. Brown, I. Astatin-211: its possible applications in cancer therapy. Int. J. Radiat. Appl. Instr. Part A., 37: 789-798, 1986.
11. Macklis, R. M., Kaplan, W. D., Ferrara, J. L., Atcher, R. W., Hines, J. J., Burakoff, S. J., and Coleman, C. N. Alpha particle radio-immunotherapy: animal models and clinical prospects. Int. J. Radiat. Oncol. Biol. Phys., 16: 1377-1387, 1989.
12. Vriesendorp, H. M., Herpst, J. M., Germack, M. A., Klein, J. L., Leichner, P. K., Loudenslager, D. M., and Order, S. E. Phase I-II studies of yttrium-labeled antifer-ritin treatment for end-stage Hodgkin's disease, including Radiation Therapy Oncology Group. 87-01. J. Clin. Oncol., 9: 918-928, 1991.
13. Larson, S. M., Carrasquillo, J. A., and Reynolds, J. C. Radioimmunodetection and radioimmunotherapy. Cancer Invest., 2: 363-381, 1984.
14. 90Yttrium antiferritin: a new therapeutic radiolabeled antibody. Int. J. Radiat. Oncol. Biol. Phys., 12: 277-281, 1986.
15. Waldmann, T. A. Multichain interleukin-2 receptor: a target for immunotherapy in lymphoma. J. Natl. Cancer Inst., 87: 914-923, 1989.
16. Waldmann, T. A., Pastan, I. H., Gansow, O. A., and Junghans, R. P. The multichain interleukin-2 receptor: a target for immunotherapy. Ann. Intern. Med., 116: 148-160, 1992.
17. Waldmann, T. A., Goldman, C. K., Bongiovanni, K. F., Sharrow, S. O., Davey, M. P., Cease, K. B., Greenberg, S. J., and Longo, D. Therapy of patients with human T-cell lymphotrophic virus I-induced adult T-cell leukemia with anti-Tac, a monoclonal antibody to the receptor for interleukin-2. Blood, 72: 1805-1816, 1988.
18. Kozak, R. W., Raubitschek, A., Mirzadeh, S., Brechbiel, M. W., Junghans, R., Gansow, O. A., and Waldmann, T. A. Nature of the bifunctional chelating agent for radioimmunotherapy with yttrium-90 monoclonal antibodies: critical factors in determining in vivo survival and organ toxicity. Cancer Res., 49: 2639-2644, 1989.
19. Kozak, R. W., Atcher, R. W., Gansow, O. A., Friedman, A. M., Hines, J. J., and Waldmann, T. A. Bismuth-212-labeled anti-Tac monoclonal antibody: α-particle-emitting radionuclides as modalities for radioimmunotherapy. Proc. Natl. Acad. Sci. USA, 83: 474-478, 1986.
20. Kozak, R. W., Waldmann, T. A., Atcher, R. A., and Gansow, O. A. Radionuclide-conjugated monoclonal antibodies: a synthesis of immunology, inorganic chemistry, and nuclear science. Trends Biotech., 4: 259-264, 1985.
21. Gansow, O. A. Status of lead and bismuth for radioimmunoimaging and radioimmunotherapy. In: A. M. Emran (ed.), New Trends in Radiopharmaceutical Synthesis, Quality Assurance, and Regulatory Control, pp. 227-246. New York: Plenum Publishing Corp., 1991.
22. 211At labeled lectins and antibodies. Int. J. Nucl. Med. Biol., 9: 167-171, 1982.
23. Gansow, O. A., Brechbiel, M. W., Pippin, C. G., McMurry, T. J., Lambrecht, R., Colcher, D., Scholm, J., Roselli, M., Strand, M., Huneke, R. B., and Ruegg, C. L. Lead and bismuth complexes of functionalized DTP A ligands and of the polyazacy-cloalkane-N-acetic acid DOTA. Utility for radioimmunoimaging and radioimmunotherapy. Antibody Immunoconj. Radiopharmaceuticals, 4: 413-425, 1991.
24. Macklis, R. M., Kinsey, B. M., Kassis, A. I., Ferrara, J. L. M., Atcher, R. W., Hines, J. J., Coleman, C. N., Adelstein, S. J., and Burakoff, S. J. Radioimmunotherapy with α-particle-emitting immunoconjugates. Science (Washington DC), 240: 1024-1026, 1988.
25. 212Bi for α-particle mediated radioimmunotherapy. J. Chem. Soc. Chem. Commun., 17: 1169-1170, 1991.
26. Brechbiel, M. W., and Gansow, O. A. Synthesis of C-functionalized trans-cyclohexyldiethylenetriaminepenta-acetic acids for labeling of monoclonal antibodies with the bismuth-212 α particle emitter. J. Chem. Soc. Perkin Trans. I, 1: 1173-1178, 1992.
27. Huneke, R. B., Pippin, C. G., Squire, R. A., Brechbiel, M. W., Gansow, O. A., and Strand, M. Effective α-particle mediated radioimmunotherapy of murine leukemia. Cancer Res., 52: 5818-5820, 1992.
28. Uchiyama, T., Broder, S., and Waldmann, T. A. A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T-cells. J. Immunol., 126: 1393-1397, 1981.
29. Tsudo, M., Kitamura, F., and Myasaka, M. Characterization of the interleukin 2 receptor β-chain using three distinct monoclonal antibodies. Proc. Natl. Acad. Sci. USA, 86: 1982-1986, 1989.
30. Hakimi, J., Ha, V. C., Lin, P., Campbell, E., Gately, M. K., Tsudo, M., Payne, P. W., Waldmann, T. A., Grant, A. J., Tsien, W. H., and Schneider, W. P. Hu-Mikβ1, a humanized antibody to the IL-2 receptor β-chain that acts synergistically with humanized anti-Tac. J. Immunol., 757: 1075-1085, 1993.
31. 224Ra. Int. J. Radiat. Appl. Inst. Part A., 39: 283, 1988.
32. Kaplan, E., and Meier, P. Nonparametric estimation from incomplete observation. J. Am. Stat. Assoc., 53: 457-481, 1958.
33. Mantel, N., and Haenszel, W. Statistical aspects of the analysis of data from retrospective studies of disease. J. Natl. Cancer Inst., 22: 719-748, 1959.
34. Rubin, L. A., Kurman, C. C., Fritz, M. E., Biddison, W. E., Boutin, B., Yarchoan, R., and Nelson, D. L. Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J. Immunol., 755: 3172-3177, 1985.
35. Waldmann, T. A. The multi-subunit interleukin-2 receptor. Annu. Rev. Biochem., 58: 875-911, 1989.
36. Macklis, R. M., Lin, J. Y., Beresford, B., Atcher, R. W., Hines, J. J., and Humm, J. L. Cellular kinetics, dosimetry, and radiobiology of α-particle radioimmunotherapy: induction of apoptosis. Radiat. Res., 130: 220-226, 1992.
37. Ruegg, C. L., Anderson-Berg, W. T., Brechbiel, M. W., Mirzadeh, S., Gansow, O. A., and Strand, M. Improved in vivo stability and tumor targeting of bismuth-labeled antibody. Cancer Res., 50: 4221-4226, 1990.
38. 212Bi) therapy. Cancer Res., 53: 5683-5689, 1993.
39. Humm, J. Dosimetric aspects of radiolabeled antibodies for tumor therapy. J. Nucl. Med., 27: 1490-1497, 1986.
40. Reilly, R. M. Radioimmunotherapy of malignancies. Clin. Pharmacol., 10: 359-374, 1991.
41. Burrows, F. J., Watanabe, Y., and Thorpe, P. E. A murine model for antibody-directed targeting of vascular endothelial cells in solid tumors. Cancer Res., 52: 5954-5962, 1992.